Abstract
N/A
Highlights
The primary efficacy endpoint was the percentage of subjects obtaining complete clearance (CC) of all baseline and new treatable molluscum lesions at Day 84
This post hoc analysis evaluates the proportion of subjects with 0 or 1 molluscum contagiosum (MC) lesions present at the End of Study Visit (EOS) Day 84 in the pooled CAMP-1 and -2 trials subjects
MC lesion counts were conducted at Treatment Visit Days 21, 42, 63 and EOS Day 84
Summary
VP-102, a proprietary drug-device combination product containing cantharidin (0.7% w/v), is under investigation for treatment of molluscum contagiosum (MC). In two phase 3 trials (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]), 528 subjects ≥ 2 years of age with MC, were randomized (3:2) to receive topical application of VP-102 or vehicle. The primary efficacy endpoint was the percentage of subjects obtaining complete clearance (CC) of all baseline and new treatable molluscum lesions at Day 84. This post hoc analysis evaluates the proportion of subjects with 0 or 1 MC lesions present at the End of Study Visit (EOS) Day 84 in the pooled CAMP-1 and -2 trials subjects. Study drug (VP-102 or vehicle) was administered topically to all treatable lesions every 21 days until clearance for a maximum of 4 applications.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
